Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02260986
Registration number
NCT02260986
Ethics application status
Date submitted
6/10/2014
Date registered
9/10/2014
Date last updated
17/10/2017
Titles & IDs
Public title
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Query!
Secondary ID [1]
0
0
R668-AD-1224
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CHRONOS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dupilumab
Treatment: Drugs - Placebo (for Dupilumab)
Other interventions - Topical Corticosteroid (TCS)
Experimental: Placebo qw - Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
Experimental: Dupilumab 300 mg q2w - Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
Experimental: Dupilumab 300 mg qw - Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
Treatment: Drugs: Dupilumab
Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Treatment: Drugs: Placebo (for Dupilumab)
Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Other interventions: Topical Corticosteroid (TCS)
All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of =2 Points at Week 16
Query!
Assessment method [1]
0
0
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score "0" or "1" and a reduction from baseline of =2 points at Week 16 were reported.
Query!
Timepoint [1]
0
0
Baseline to Week 16
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (=75% Improvement From Baseline) at Week 16
Query!
Assessment method [1]
0
0
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved =75% overall improvement in EASI score from baseline to Week 16.
Query!
Timepoint [1]
0
0
Baseline to Week 16
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Improvement (Reduction =4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
Query!
Assessment method [2]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Participants achieving a reduction of =4 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported.
Query!
Timepoint [2]
0
0
Baseline to Week 16
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Improvement (Reduction =3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
Query!
Assessment method [3]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Participants achieving a reduction of =3 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported.
Query!
Timepoint [3]
0
0
Baseline to Week 16
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of =2 Points at Week 52
Query!
Assessment method [4]
0
0
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of "0" or "1" and a reduction from baseline of =2 points at Week 52 were reported.
Query!
Timepoint [4]
0
0
Baseline to Week 52
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (=75% Improvement From Baseline) at Week 52
Query!
Assessment method [5]
0
0
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved =75% overall improvement in EASI score from baseline to Week 52.
Query!
Timepoint [5]
0
0
Baseline to Week 52
Query!
Secondary outcome [6]
0
0
Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16
Query!
Assessment method [6]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]).
Query!
Timepoint [6]
0
0
Baseline to Week 16
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Improvement (Reduction =4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52
Query!
Assessment method [7]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Participants achieving a reduction of =4 points from baseline in weekly average of peak daily pruritus NRS score at Week 52 were reported.
Query!
Timepoint [7]
0
0
Baseline to Week 52
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Improvement (Reduction =3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52
Query!
Assessment method [8]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Participants achieving a reduction of =3 points from baseline in weekly average of peak daily pruritus NRS score at Week 52 were reported.
Query!
Timepoint [8]
0
0
Baseline to Week 52
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Improvement (Reduction =4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 24
Query!
Assessment method [9]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Participants achieving a reduction of =4 points from baseline in weekly average of peak daily pruritus NRS score at Week 24 were reported.
Query!
Timepoint [9]
0
0
Baseline to Week 24
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Improvement (Reduction =4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4
Query!
Assessment method [10]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Participants achieving a reduction of =4 points from baseline in weekly average of peak daily pruritus NRS score at Week 4 were reported.
Query!
Timepoint [10]
0
0
Baseline to Week 4
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Improvement (Reduction =4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2
Query!
Assessment method [11]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Participants achieving a reduction of =4 points from baseline in weekly average of peak daily pruritus NRS score at Week 2 were reported.
Query!
Timepoint [11]
0
0
Baseline to Week 2
Query!
Secondary outcome [12]
0
0
Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16
Query!
Assessment method [12]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]).
Query!
Timepoint [12]
0
0
Baseline to Week 16
Query!
Secondary outcome [13]
0
0
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16
Query!
Assessment method [13]
0
0
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Query!
Timepoint [13]
0
0
Baseline to Week 16
Query!
Secondary outcome [14]
0
0
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 16
Query!
Assessment method [14]
0
0
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]). It was reported as a percentage of all major body sections combined.
Query!
Timepoint [14]
0
0
Baseline to Week 16
Query!
Secondary outcome [15]
0
0
Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16
Query!
Assessment method [15]
0
0
SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [15]
0
0
Baseline to Week 16
Query!
Secondary outcome [16]
0
0
Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16
Query!
Assessment method [16]
0
0
The DLQI was a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL.
Query!
Timepoint [16]
0
0
Baseline to Week 16
Query!
Secondary outcome [17]
0
0
Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16
Query!
Assessment method [17]
0
0
The POEM was a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life [QOL]).
Query!
Timepoint [17]
0
0
Baseline to Week 16
Query!
Secondary outcome [18]
0
0
Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16
Query!
Assessment method [18]
0
0
HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression.
Query!
Timepoint [18]
0
0
Baseline to Week 16
Query!
Secondary outcome [19]
0
0
Percent Change From Baseline in Total Global Individual Signs Score (GISS) to Week 16
Query!
Assessment method [19]
0
0
Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).
Query!
Timepoint [19]
0
0
Baseline to Week 16
Query!
Secondary outcome [20]
0
0
Proportion of Topical Atopic Dermatitis Medication-Free Days Through Week 52
Query!
Assessment method [20]
0
0
Proportion of topical AD medication-free days through Week 52 was calculated as the number of days that a participant used neither topical corticosteroid (TCS)/ topical calcineurin inhibitors (TCI) nor system rescue therapy divided by the study days of each period.
Query!
Timepoint [20]
0
0
Baseline to Week 52
Query!
Secondary outcome [21]
0
0
Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 2
Query!
Assessment method [21]
0
0
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]).
Query!
Timepoint [21]
0
0
Baseline to Week 2
Query!
Secondary outcome [22]
0
0
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 52
Query!
Assessment method [22]
0
0
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Query!
Timepoint [22]
0
0
Baseline to Week 52
Query!
Secondary outcome [23]
0
0
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 52
Query!
Assessment method [23]
0
0
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]). It was reported as a percentage of all major body sections combined.
Query!
Timepoint [23]
0
0
Baseline to Week 52
Query!
Secondary outcome [24]
0
0
Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 52
Query!
Assessment method [24]
0
0
SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [24]
0
0
Baseline to Week 52
Query!
Secondary outcome [25]
0
0
Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 52
Query!
Assessment method [25]
0
0
Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).
Query!
Timepoint [25]
0
0
Baseline to Week 52
Query!
Secondary outcome [26]
0
0
Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 52
Query!
Assessment method [26]
0
0
The DLQI was a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL.
Query!
Timepoint [26]
0
0
Baseline to Week 52
Query!
Secondary outcome [27]
0
0
Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 52
Query!
Assessment method [27]
0
0
The POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life [QOL]).
Query!
Timepoint [27]
0
0
Baseline to Week 52
Query!
Secondary outcome [28]
0
0
Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 52
Query!
Assessment method [28]
0
0
HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire is scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression.
Query!
Timepoint [28]
0
0
Baseline to Week 52
Query!
Secondary outcome [29]
0
0
Number of Flares Through Week 52
Query!
Assessment method [29]
0
0
Atopic dermatitis (AD) flares were defined as worsening of the disease that required escalation/intensification of AD treatment. Number of flares occurred in the participants starting from first dose through Week 52 were reported.
Query!
Timepoint [29]
0
0
Baseline up to Week 52
Query!
Secondary outcome [30]
0
0
Number of Serious Treatment Emergent Adverse Events (TEAEs) Leading to Study Drug Discontinuation Through Week 52
Query!
Assessment method [30]
0
0
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. A Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
Query!
Timepoint [30]
0
0
Baseline up to Week 52
Query!
Secondary outcome [31]
0
0
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Week 52
Query!
Assessment method [31]
0
0
Any untoward medical occurrence in a participants who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.
Query!
Timepoint [31]
0
0
Baseline up to Week 52
Query!
Secondary outcome [32]
0
0
Number of Skin Infection TEAEs (Excluding Herpetic Infections) From Baseline Through Week 52
Query!
Assessment method [32]
0
0
Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.
Query!
Timepoint [32]
0
0
Baseline up to Week 52
Query!
Secondary outcome [33]
0
0
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52
Query!
Assessment method [33]
0
0
Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.
Query!
Timepoint [33]
0
0
Baseline up to Week 52
Query!
Secondary outcome [34]
0
0
Number of Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52
Query!
Assessment method [34]
0
0
Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.
Query!
Timepoint [34]
0
0
Baseline up to Week 52
Query!
Eligibility
Key inclusion criteria
Key
1. Chronic AD that had been present for at least 3 years before the screening visit;
2. Documented recent history (within 6 months before the screening visit) of inadequate
response to a sufficient course of out-patient treatment with topical AD
medication(s).
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participation in a prior Dupilumab clinical trial;
2. Important side effects of topical medication (e.g. intolerance to treatment,
hypersensitivity reactions, significant skin atrophy, systemic effects), as assessed
by the investigator or treating physician;
3. Having used any of the following treatments within 4 weeks before the baseline visit,
or any condition that, in the opinion of the investigator, was likely to require such
treatment(s) during the first 2 weeks of study treatment:
1. Immunosuppressive/immunomodulating drugs (e.g, systemic steroids, cyclosporine,
mycophenolate-mofetil, Janus kinase inhibitors, interferon-gamma [IFN-?],
azathioprine, methotrexate, etc.);
2. Phototherapy for AD;
4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit;
5. History of human immunodeficiency virus (HIV) infection or positive HIV serology at
screening;
6. Positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or
hepatitis C antibody at the screening visit;
7. Active or acute infection requiring systemic treatment within 2 weeks before baseline
visit;
8. Known or suspected history of immunosuppression;
9. Pregnant or breastfeeding women, or planning to become pregnant or breastfeed during
the participant's participation in this study.
Note: The eligibility criteria listed above is not intended to contain all considerations
relevant to a participant's potential participation in a clinical trial therefore not all
inclusion/ exclusion criteria are listed.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
740
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
- Phillip
Query!
Recruitment hospital [2]
0
0
- Kogarah
Query!
Recruitment hospital [3]
0
0
- Benowa
Query!
Recruitment hospital [4]
0
0
- Dulwich
Query!
Recruitment hospital [5]
0
0
- Hectorville
Query!
Recruitment hospital [6]
0
0
- Carlton
Query!
Recruitment postcode(s) [1]
0
0
- Phillip
Query!
Recruitment postcode(s) [2]
0
0
- Kogarah
Query!
Recruitment postcode(s) [3]
0
0
- Benowa
Query!
Recruitment postcode(s) [4]
0
0
- Dulwich
Query!
Recruitment postcode(s) [5]
0
0
- Hectorville
Query!
Recruitment postcode(s) [6]
0
0
- Carlton
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nebraska
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nevada
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Mexico
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oklahoma
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oregon
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Utah
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Vermont
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Virginia
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Washington
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
British Columbia
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Ontario
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Quebec
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Hradec Kralove
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Nachod
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Praha 10
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Praha 5
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Svitavy
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Usti nad Labem
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Békés
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Jász-Nagykun-Szolnok
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Veszprém
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Budapest
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Ancona
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Bologna
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Brescia
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Novara
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Pavia
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Perugia
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Roma
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Fukuoka
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Hyôgo
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Kanagawa
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Kumamoto
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Saitama
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Shizuoka
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Tokyo
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Tôkyô
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Gyeonggido
Query!
Country [56]
0
0
Korea, Republic of
Query!
State/province [56]
0
0
Seoul Teugbyeolsi
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Seodaemun-gu
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Uijeongbu-si
Query!
Country [59]
0
0
Netherlands
Query!
State/province [59]
0
0
Noord-Brabant
Query!
Country [60]
0
0
Netherlands
Query!
State/province [60]
0
0
Noord-Holland
Query!
Country [61]
0
0
Netherlands
Query!
State/province [61]
0
0
Zuid-Holland
Query!
Country [62]
0
0
Netherlands
Query!
State/province [62]
0
0
Groningen
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
Utrecht
Query!
Country [64]
0
0
New Zealand
Query!
State/province [64]
0
0
South Island
Query!
Country [65]
0
0
New Zealand
Query!
State/province [65]
0
0
Auckland
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Dolnoslaskie
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Lubelskie
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Mazowieckie
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Malopolskie
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Opolskie
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Podkarpackie
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Podlaskie
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Pomorskie
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Wielkopolskie
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Zachodniopomorskie
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Gdynia
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Lódzkie
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Slaskie
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Swietokrzyskie
Query!
Country [80]
0
0
Romania
Query!
State/province [80]
0
0
Brasov
Query!
Country [81]
0
0
Romania
Query!
State/province [81]
0
0
Bucuresti
Query!
Country [82]
0
0
Romania
Query!
State/province [82]
0
0
Cluj
Query!
Country [83]
0
0
Romania
Query!
State/province [83]
0
0
Dolj
Query!
Country [84]
0
0
Romania
Query!
State/province [84]
0
0
Mures
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Cataluña
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Alicante
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Madrid
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Angus
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Birmingham
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Glasgow City
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Kent
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Middlesex
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Liverpool
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Manchester
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Reading
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Regeneron Pharmaceuticals
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Sanofi
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of the study was to demonstrate the efficacy of Dupilumab administered
concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with
moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with
TCS.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02260986
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trial Management
Query!
Address
0
0
Regeneron Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02260986
Download to PDF